DK2001456T3 - Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser - Google Patents
Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelserInfo
- Publication number
- DK2001456T3 DK2001456T3 DK07727719.2T DK07727719T DK2001456T3 DK 2001456 T3 DK2001456 T3 DK 2001456T3 DK 07727719 T DK07727719 T DK 07727719T DK 2001456 T3 DK2001456 T3 DK 2001456T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- opioid receptor
- receptor antagonist
- kappa opioid
- containing compositions
- Prior art date
Links
- 208000018459 dissociative disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002618 kappa opiate receptor antagonist Substances 0.000 title 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract 1
- 108020001588 κ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| PCT/EP2007/053248 WO2007115975A2 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2001456T3 true DK2001456T3 (da) | 2010-04-12 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07727719.2T DK2001456T3 (da) | 2006-04-04 | 2007-04-03 | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (da) |
| EP (1) | EP2001456B1 (da) |
| JP (1) | JP5128578B2 (da) |
| AT (1) | ATE450256T1 (da) |
| AU (1) | AU2007236003B2 (da) |
| CA (1) | CA2646899C (da) |
| CY (1) | CY1109862T1 (da) |
| DE (1) | DE502007002185D1 (da) |
| DK (1) | DK2001456T3 (da) |
| EA (1) | EA014820B1 (da) |
| ES (1) | ES2337622T3 (da) |
| HR (1) | HRP20100113T1 (da) |
| PL (1) | PL2001456T3 (da) |
| PT (1) | PT2001456E (da) |
| RS (1) | RS51211B (da) |
| SI (1) | SI2001456T1 (da) |
| WO (1) | WO2007115975A2 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2252581B1 (en) | 2008-01-22 | 2012-06-20 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| EP3082816B1 (en) | 2013-12-20 | 2019-03-20 | Indivior UK Limited | Intranasal naloxone compositions and methods of making and using same |
| JP6448645B2 (ja) * | 2013-12-20 | 2019-01-09 | ハー・ルンドベック・アクチエゼルスカベット | メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 |
| ES2658766T3 (es) | 2014-04-28 | 2018-03-12 | Orphomed, Inc. | Dímero de buprenorfina y uso en el tratamiento de trastornos gastrointestinales |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US20220370409A1 (en) | 2021-05-04 | 2022-11-24 | Janssen Pharmaceuticals, Inc. | Compositions And Methods For The Treatment Of Depression |
| TW202345796A (zh) | 2022-03-07 | 2023-12-01 | 美商健生醫藥公司 | 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| WO2002013759A2 (en) | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| AU2002231206A1 (en) | 2000-12-21 | 2002-07-01 | The Mclean Hospital Corporation | Treatment of depression |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| EP1613617A4 (en) * | 2003-04-04 | 2009-02-18 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS |
| BRPI0508254A (pt) | 2004-03-02 | 2007-07-24 | Pharmacia Corp | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos |
| DK1758596T3 (da) * | 2004-05-26 | 2010-07-26 | Inotek Pharmaceuticals Corp | Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf |
| EP1750675B1 (en) * | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
-
2007
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de active Application Filing
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
- 2010-03-02 HR HR20100113T patent/HRP20100113T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2001456B1 (de) | 2009-12-02 |
| CA2646899C (en) | 2014-05-06 |
| SI2001456T1 (sl) | 2010-04-30 |
| JP2009532434A (ja) | 2009-09-10 |
| CY1109862T1 (el) | 2014-09-10 |
| RS51211B (sr) | 2010-12-31 |
| EP2001456A2 (de) | 2008-12-17 |
| AU2007236003A1 (en) | 2007-10-18 |
| EA200802104A1 (ru) | 2009-04-28 |
| US20090181999A1 (en) | 2009-07-16 |
| ATE450256T1 (de) | 2009-12-15 |
| WO2007115975A2 (de) | 2007-10-18 |
| CA2646899A1 (en) | 2007-10-18 |
| HRP20100113T1 (hr) | 2010-04-30 |
| AU2007236003B2 (en) | 2012-10-18 |
| EA014820B1 (ru) | 2011-02-28 |
| PL2001456T3 (pl) | 2010-05-31 |
| JP5128578B2 (ja) | 2013-01-23 |
| ES2337622T3 (es) | 2010-04-27 |
| PT2001456E (pt) | 2010-03-03 |
| US8063059B2 (en) | 2011-11-22 |
| WO2007115975A3 (de) | 2008-02-14 |
| DE502007002185D1 (de) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| CY1110882T1 (el) | Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης | |
| DE602007012072D1 (de) | Orantagonisten | |
| DK1729753T3 (da) | Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet | |
| CY1112969T1 (el) | Ανταγωνιστες πιριδυλ πιπεριδινης του υποδοχεα ορεξινης | |
| IL208895A0 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| SG163564A1 (en) | Kinin antagonists for treating bladder dysfunction | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| HK1120442A1 (en) | Novel opioid antagonists | |
| UA112514C2 (uk) | АНТАГОНІСТИ C5aR | |
| ATE509928T1 (de) | 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten | |
| DK1711465T3 (da) | Hydroisoindolin-tachykinikreceptorantagonister | |
| DK1973886T3 (da) | Prokineticin-1-receptor-antagonister | |
| DK1943242T3 (da) | Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer | |
| ATE481405T1 (de) | Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors | |
| DK2001456T3 (da) | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| ZA200710611B (en) | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases | |
| CL2007002611A1 (es) | Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad. | |
| EP2075252A4 (en) | NK1 Receptor Antagonists COMPOSITION | |
| DK2091938T3 (da) | Piperidinylaminopyridaziner og anvendelse deraf som hurtigt opløsende antagonister af dopamin-2-receptorer | |
| ZA200900613B (en) | 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders | |
| ATE469900T1 (de) | Spiropiperidinderivate als antagonisten des via- rezeptors | |
| IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
| DK2300474T3 (da) | Spiro(piperidin-4,2'-pyrrolidin)-1-(3,5-trifluormethyl-phenyl)methylcarboxamider som nk1-tachikyninreceptor antagonister |